Medicinal Cannabis Debate
Full Debate: Read Full DebateLisa Cameron
Main Page: Lisa Cameron (Conservative - East Kilbride, Strathaven and Lesmahagow)Department Debates - View all Lisa Cameron's debates with the Department of Health and Social Care
(2 years, 11 months ago)
Commons ChamberI congratulate the hon. Member for Edinburgh West (Christine Jardine) on bringing this debate forward, and it is a pleasure to follow the right hon. Member for Hemel Hempstead (Sir Mike Penning). He is a man who speaks with great passion for what he believes in, and I have been very fortunate to be able to support him in bringing this issue forward.
I rise to speak about one of my constituents. Darren and Danielle are the parents of little Sophia. I have absolutely no doubt that the reason why Sophia has improved so fantastically, way beyond what we ever hoped, is because of medicinal cannabis. Parents, as parents do, speak for their children and want the best for them. I brought Danielle over here and we met the previous Health Minister, who heard her story for the first time. As a result of hearing that story, he did his best to help us move forward to the next stage. A lot of people have helped. We would never have done any of these things without myriad people, including the right hon. Member for Hemel Hempstead and his friends and colleagues. Sophia is a lovely bright wee girl whose life was a litany of multiple seizures. She is a different girl today because of medicinal cannabis. I am very clear about what I want to see in relation to medicinal cannabis. I see its specific benefit for young people.
I am very fortunate to be a member of many organisations back home. One is the Royal Black Preceptory, and who were there at the side of the road in Newtownards on the last Saturday in August but Sophia, Danielle and Darren? That wee girl, who I had not seen for ages—for a couple of years at least, because of covid—was at the side of the road and she was as bright as a bean. Her mum and dad were pointing me out in the parade so they could say thank you for all we had done. Honestly, what did we do? All we did, really, was what any parent would do for their child, and that is what it is all about.
I thank the hon. Gentleman for giving way and for pointing out just what it means to families to have this opportunity. In my own constituency, Cole Thompson and his mother Lisa Quarrell have really fought and campaigned to pay for this medication. Aside from the financial costs, I hope he agrees that we must also recognise the psychological stress and turmoil we are continually putting these families through month after month after month. It really is incumbent on the Government to address that, because it is simply not fair: it is not fair on the children and it is not fair on the families.
I thank the hon. Lady for her intervention. That is exactly how I feel, and I think it is exactly how we all feel as elected representatives on behalf of our constituents. I can well recall the bad old days of the pressure that was on the family: the pressure on the parents, the pressure on the child and the pressure on their friends, with all the multiple issues they had to address. There is an evidential base. It is as clear as a bell. I can see it in that wee girl Sophia. I can see it in the improvement that she has quite clearly made. That is why I totally support this product. I believe the evidential base is overwhelming. I can vouch for that, as I see that lovely wee girl and the improvements she has had.
My hon. Friend the Member for Belfast East (Gavin Robinson) sent me a letter, which I will record for Hansard if I can, written by his constituent, a fellow called Robin Emerson, whose daughter is a wee girl called Jorja. There is also an evidential base in her improvement. My hon. Friend very kindly gave me a copy of the letter last week, which refers to
“an important intervention to enable a number of children suffering with epilepsy to receive a treatment containing Cannabidiol (CBD) and Tetrahydrocannabinol (THC). This has made a crucial difference to their quality of life over the past two years”.
In some cases, quite honestly Mr Speaker, I believe they save lives. They definitely do. In my heart I believe that, which is why I am here tonight to speak on this matter. I feel it is so important.
All three Members rose at the same time. I will make my next point before I take interventions.
While the evidence base remains limited, I am sure that everybody, including clinicians in this place, will agree that decisions on whether to prescribe, as with any other medicine, have to remain clinical decisions. A doctor would not appreciate me in their consulting room telling them that they did not know their job as a doctor.
I would like to reassure the hon. Lady that we do look elsewhere, but it fundamentally comes back to the fact that observational trials on very small cohorts are not the best way to develop the policy, going forward, to treat these individuals. That is notwithstanding the fact that the observations of all the parents I have met, and others who have seen their children benefit, are the foundation for making us try to put our shoulders to the wheel in order to do better. I think there is that tension.
Looking across other countries, my hon. Friend the Member for Windsor (Adam Afriyie) said, “If they can do it, why can’t we?” What is needed to support routine prescribing is the evidence base of safety and efficacy, public funding and cost-effectiveness. This is the system that we use in the UK for all medicines and medical devices, and it is really difficult to see a case for why cannabis should be treated differently from that on a broader spectrum, particularly when we take into account the comment by my hon. Friend the Member for Reigate (Crispin Blunt) that there is a need to look at how these medicines may help others suffering from chronic pain. I have been told that multiple sclerosis and palliative care are other areas, and so on. If we are going to broaden this, then we must look to do the job properly.
I thank the Minister for grappling with what is a very complex matter. I totally understand what she is saying. I can understand some clinicians’ reluctance because they do not want to prescribe something when they do not know what is contraindicated in relation to other conditions and they do not want to do harm. But this must potentially be done where the children are already benefiting from some kind of expedited process to ensure that they can have the prescriptions and that parents are not having to try to fund that in so many different ways, causing that stress. There must then be some kind of expedited clinical trial that shows that clinicians more broadly can have the confidence that they are prescribing medications that will support conditions, do no harm and would not be contraindicated or cost children or adults their lives if prescribed to the wrong individuals.
I thank the hon. Lady because she encapsulates in a nutshell what the challenges are. This is extremely difficult without that knowledge of what the contraindications are. I was trying to suggest, perhaps not as eloquently as I could have done, that we need these different bits in order to make the policy work. As the House has heard, the current Health Secretary was the Home Secretary when he changed the law, and at our very first meeting, he told me it was one of the things he was very keen to see us move forward on.